To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
A phase 1/2 trial of SG2918 in multiple myeloma, run by Hangzhou Sumgen Biotech Co., Ltd., now recruiting.
Overview
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT07454187 by Hangzhou Sumgen Biotech Co., Ltd., with 40 participants planned, started 2026-04-16 and due to reach its primary completion in 2027-09-30. Interventions recorded: SG2918.
Similar pages
not linked directly; found by shared links- TreatmentSG301
Shares Hangzhou Sumgen Biotech, Multiple myeloma and the tag pipeline.
- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.